BCM
PFE icon

Brooktree Capital Management’s Pfizer PFE Stock Holding History

Brooktree Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Sell
101,128
-307
-0.3% -$8.03K 1.59% 18
2026
Q1 		$2.85M Sell
101,435
-19,075
-16% -$508K 2.26% 13
2025
Q4 		$3M Sell
120,510
-9,136
-7% -$230K 2% 11
2025
Q3 		$3.3M Buy
129,646
+8,291
+7% +$205K 2.1% 12
2025
Q2 		$2.94M Buy
121,355
+3,184
+3% +$74.3K 1.92% 12
2025
Q1 		$2.99M Buy
118,171
+2,788
+2% +$73K 2.25% 11
2024
Q4 		$3.06M Buy
115,383
+1,389
+1% +$37.7K 2.27% 12
2024
Q3 		$3.3M Buy
113,994
+1,316
+1% +$38.4K 2.68% 12
2024
Q2 		$3.15M Sell
112,678
-8,574
-7% -$236K 2.7% 12
2024
Q1 		$3.36M Buy
121,252
+6,117
+5% +$170K 2.6% 14
2023
Q4 		$3.31M Sell
115,135
-9,877
-8% -$299K 2.68% 15
2023
Q3 		$4.15M Buy
125,012
+3,640
+3% +$129K 3.46% 13
2023
Q2 		$4.45M Sell
121,372
-4,228
-3% -$165K 3.38% 12
2023
Q1 		$5.12M Sell
125,600
-1,659
-1% -$71.7K 3.99% 12
2022
Q4 		$6.52M Sell
127,259
-2,557
-2% -$123K 5.36% 8
2022
Q3 		$5.68M Buy
129,816
+5,650
+5% +$275K 4.68% 8
2022
Q2 		$6.51M Buy
124,166
+2,621
+2% +$134K 4.89% 9
2022
Q1 		$6.29M Buy
121,545
+8,432
+7% +$438K 4.1% 9
2021
Q4 		$6.68M Sell
113,113
-1,206
-1% -$59.8K 4.08% 9
2021
Q3 		$4.92M Buy
114,319
+2,302
+2% +$102K 3.13% 12
2021
Q2 		$4.39M Buy
112,017
+17,348
+18% +$675K 2.82% 12
2021
Q1 		$3.43M Buy
94,669
+1,965
+2% +$69.8K 2.3% 16
2020
Q4 		$3.41M Sell
92,704
-6,109
-6% -$224K 2.51% 12
2020
Q3 		$3.44M Buy
98,813
+4,389
+5% +$154K 2.91% 11
2020
Q2 		$2.93M Buy
94,424
+1,657
+2% +$56.3K 2.75% 13
2020
Q1 		$2.87M Buy
92,767
+16,725
+22% +$570K 3.33% 11
2019
Q4 		$2.83M Buy
+76,042
New +$2.71M 2.59% 17

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brooktree Capital Management's PFE Position: Q2 2026 in Review

Brooktree Capital Management reduced its Pfizer (PFE) stake by 0.3% in Q2 2026, selling an estimated $8.03K and leaving 101,128 shares worth $2.44M. The position accounts for 1.59% of the portfolio, ranked #18.

Brooktree Capital Management first reported a position in PFE in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.68M in Q4 2021. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Brooktree Capital Management held 101,128 shares of Pfizer worth $2.44M as of Q2 2026.
  • Brooktree Capital Management sold 307 Pfizer shares in Q2 2026, an estimated $8.03K.
  • Pfizer made up 1.59% of Brooktree Capital Management's portfolio in Q2 2026, its #18 holding.
  • Brooktree Capital Management first reported a position in Pfizer in Q4 2019 and has held it in 27 quarters since.
  • Brooktree Capital Management's Pfizer position peaked at $6.68M in Q4 2021.
  • 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Brooktree Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.